LILRB1 Antibody / ILT-2

Immunoprecipitation: 1-2ug per 100-500ug of total protein (1ml of cell lysate),Western blot: 1-2ug/ml,Flow cytometry: 1-2ug/million cells

Optimal dilution of the LILRB1 antibody should be determined by the researcher.

Leukocyte immunoglobulin-like receptors (LIRs) are members of the immunoglobulin superfamily of glycoproteins and are predominantly expressed by monocytes, B cells, dendritic cells, natural killer (NK) cells, peripheral blood leukocytes and tissues such as placenta, lung and liver. Immunoglobulin-like transcript 2 (ILT-2), also known as CD85 or MIR7, is a 650 amino acid glycoprotein that contains a 23 amino acid signal peptide, 4 extracellular C2-type IGSF domains and 4 intracellular ITIM motifs. ILT-2 can bind major histocompatability (MHC) class I molecules and inhibit cell termination by natural killer (NK) and T cells, and inhibit Ca2+ mobilization in myeloid cells triggered through the B cell antigen receptor and histocompatibility leukocyte antigens (HLA)-DR. ILT-2 contains four putative cytoplasmic tyrosine-based inhibitory motifs and upon tyrosine phosphorylation, associates with the tyrosine phosphatase SHP-1.

Purified

1 mg/ml in 1X PBS; BSA free, sodium azide free

Hairy cell leukemia cells were used as the immunogen for the LILRB1 antibody.

This LILRB1 antibody is available for research use only.

Cell surface

Protein G affinity chromatography

Q8NHL6